Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 2/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.36 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.35 |
| ▸ | ENPEP | Q07075 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 3/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23855053 | 1.00 | MAPT (0.43) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL16501784 | 0.82 | KDM4E (0.48) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL394954 | 0.79 | TGFBR1 (0.36) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL23855055 | 0.79 | TGFBR1 (0.36) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL1290540 | 0.77 | ALDH1A1 (0.37) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL793417 | 0.77 | GABRR1 (0.33) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL3899245 | 0.77 | GRN (0.31) | MAPTKDM4ETHRBALOX15NFKB1 | |
| SCHEMBL1132971 | 0.76 | MEN1 (0.31) | — | |
| SCHEMBL5682510 | 0.76 | CYP2D6 (0.33) | MAPTKDM4ENFKB1THPOBLM | |
| SCHEMBL19210480 | 0.76 | CYP2D6 (0.48) | MAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300912-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | Ikena Oncology, Inc. | 2021-09-30 | — | — | US | disclosed |
| WO-2021127302-A1 | 2-(1H-INDOLE-3-CARBONYL)-THIAZOLE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS FOR THE TREATMENT OF E.G. ANGIOGENESIS IMPLICATED OR INFLAMMATORY DISORDERS | Ikena Oncology, Inc. (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-1773343-A4 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2009-05-13 | — | — | EP | disclosed |
| EP-1824497-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-08-29 | — | — | EP | disclosed |
| EP-1773343-A1 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006050943-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006017326-A1 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300912-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | AHR, ARNT, HCAR1 | MAPT 4673/4885KDM4E 2120/4885THRB 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.